– USA, IL – MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs, today announced the appointment of Steve Chaouki to its Board of Directors.
“We are pleased to welcome Steve to the MAIA board,” said Chairman and CEO, Dr. Vlad Vitoc. “Steve is an experienced financial leader who has deep expertise across many diverse and large markets. We are eager to benefit from his background as we grow the company and advance as a clinical-stage organization.”
About Steve Chaouki
Mr. Chaouki is a finance executive with over two decades of experience across capital markets and financial services and he currently serves as the President, U.S. Markets & Consumer Interactive of TransUnion, overseeing two TransUnion business lines. The U.S. Markets line provides information and insights to business customers across financial services, insurance, public sector, media, and diversified markets. The Consumer Interactive line provides credit, financial, and identity protection services to consumers. He previously held the role of EVP, Financial Services of TransUnion, responsible for the company’s financial services business, which provides solutions to banks, credit unions, capital markets, financial services resellers, auto lenders, and other customers.
Mr. Chaouki said, “MAIA is doing important work to improve and extend the lives of people fighting cancer, and I am excited to work with the team at MAIA to fully realize the potential of its targeted approach in immuno-oncology and provide much-needed therapeutic benefit to patients living with cancer.”
Mr. Chaouki earned an M.B.A. from the University of Chicago Booth School of Business and a B.S.B.A. from Boston University.
About MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Programs include THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells, and pre-clinical evaluation of potentially novel compounds targeting androgen receptor and direct FKBP52 co-chaperone inhibition.
For more information: https://maiabiotech.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.